With a $1.94 billion cash cushion, 2026 revenue guidance of $700–800 million and key FDA-aligned trials, PTC is funding growth while targeting cash-flow breakeven. The company's newly launched Sephience generated $112.1 million in 2025 net revenue since launch, with $92.5 million in fourth-quarter sales alone and reaching 946 patients worldwide by year-end.
Cyborg Score Rationale
PTC guides 19–36% year-over-year revenue growth in 2026, supported by strong Sephience launch momentum. The company has substantial cash reserves and FDA-aligned pipeline programs, though PTC recently withdrew its NDA resubmission for Translarna for nonsense mutation DMD following FDA feedback.
Top Insights
Sephience launched in 2025 with 946 patients reached globally by year-end, demonstrating strong commercial uptake in PKU treatment
FDA-aligned Phase 3 trial design for votoplam HD with openness to Accelerated Approval pathway given significant unmet need
Company sold remaining Evrysdi royalty rights for $240M upfront plus up to $60M in milestones while retaining a $150M milestone right, demonstrating strategic financial management
Company targeting cash-flow breakeven in 2026 while continuing Sephience launch momentum and advancing earlier-stage programs
Named Competitors
Evrysdi — SMA treatment; royalty rights sold by PTC to Royalty Pharma
Vatiquinone — Friedreich's ataxia treatment in Phase 3 development
Translarna — Nonsense mutation DMD; NDA withdrawn in Feb 2026
Recent Developments
(Feb 2026) Withdrawn Translarna NDA resubmission for nonsense mutation DMD after FDA feedback on insufficient evidence of effectiveness
(Jan 2026) Reported 2025 product and royalty revenue of $823.4M, exceeding guidance; 2026 guidance of $700–800M product revenue
(Dec 2025) Sold remaining Evrysdi royalty rights to Royalty Pharma for $240M upfront plus potential $60M milestones; approved Sephience in Japan
(Dec 2025) FDA End-of-Phase 2 meeting: alignment on votoplam Phase 3 design for Huntington's disease with potential Accelerated Approval pathway
Open the full interactive PTC Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.